Day: June 20, 2025

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly people TARRYTOWN, N.Y. and PARIS, June 20, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with...

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoidApproval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating, and relapsing rare skin disease affecting approximately 27,000 adults in the US whose disease is uncontrolled by systemic corticosteroids Dupixent is now approved in the US to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly peopleParis and Tarrytown, NY, June 20, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with bullous...

The shareholders of AS LHV Varahaldus, AS LHV Kindlustus, and AS LHV Finance, belonging to the consolidation group of AS LHV Group, intend to elect, starting from 22 July 2025, Mihkel Torim as a new Member of the Supervisory Board, who will also assume the position of the Chairman of the Management Board of AS LHV Group on the same date. The Member of the Supervisory Board is elected for up to five years. The decision on the compliance of the new Member of the Supervisory Board with the suitability requirements will also be made by the Financial Supervision Authority. Mihkel Torim joined LHV at the beginning of 2023, when he assumed responsibility for managing and developing the investment banking operations of LHV Pank. Prior to that, he held senior positions at Swedbank, including the Head of Baltic Investment Banking, and also led the...

AVTL to develop ammonia terminal in Pipavav Rotterdam, the Netherlands, 20 June 2025 In India, AVTL, will develop a brownfield ammonia terminal at the existing Pipavav location. The terminal will be the first independent ammonia storage terminal in India.  The terminal will facilitate ammonia imports, serving the extensive fertilizer market. Next to the usage in the fertilizer industry, ammonia is a key carrier for hydrogen and identified as an important product in the energy transition. The terminal will support green ammonia exports in the future, this ties in with the strategy to accelerate towards infrastructure for the energy transition. The terminal is designed as a third-party, independent storage facility with a storage capacity of around 36,000 metric tons and is expected to be commissioned by the end of 2026. Its customers...

Clermont-Ferrand (France), June 20, 2025 (6:45 am CEST). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the results of its Ordinary and Extraordinary general Meeting of June 19, 2025. Shareholders physically present, represented or voting by post totalled 31.18% of the shares composing the Company’s share capital and carrying voting rights, and 31.25% of the voting rights. All the resolutions on the agenda were approved, excepted the 21st Resolution. It has notably been approved the renewal of the term of office of Business Opportunities for L’Oréal Development (BOLD), Michelin Ventures, Ms Isabelle Parize, Mr Vincent Kamel, Ms Karine Auclair and Mr Mateus Schreiner Garcez Lopes as directors. The...

Reference is made to the stock exchange notice from IDEX Biometrics ASA on 15 June 2025 regarding the share issue to personnel. The subscription and allocation have been completed on 19 June 2025. IDEX Biometrics ASA informs of primary insider transactions as listed in the attached notifications. For further information contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@idexbiometrics.com About this notice: This notice was issued by Kristian Flaten, CFO, on 20 June 2025 at 04:00 CET on behalf of IDEX Biometrics ASA. This information is subject to the disclosure requirements pursuant to Article 19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act.Attachments2025-06-19 Annika Olsson notice2025-06-19 Morten Opstad notice2025-06-19 K Konsult...

IDEX Biometrics ASA (“IDEX”) discloses the following on behalf of a shareholder. Reference is made to the stock exchange notice from IDEX Biometrics ASA on 15 June 2025 regarding the share issue to personnel, and the notice regarding mandatory notification of trades on 20 June 2025. The subscription and allocation have been completed on 19 June 2025. Anders Storbråten, including associated company Pinchcliffe AS, will hold 975,635,000 shares in IDEX. Following registration of the share capital increase for the personnel placement, the ownership will represent 20.62 % of the shares and voting rights in IDEX. About this notice: This notice was issued by Kristian Flaten, CFO, on 20 June 2025 at 04:22 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA)...

IDEX Biometrics ASA (“IDEX”) discloses the following on behalf of a shareholder. Reference is made to the stock exchange notice from IDEX Biometrics ASA on 15 June 2025 regarding the share issue to personnel. The subscription and allocation have been completed on 19 June 2025. Sundt AS holds 230,491,498 shares in IDEX. This is unchanged from the previous notice on 14 April 2025. Following registration of the share capital increase for the personnel placement, the ownership will represent 4.87 % of the shares and voting rights in IDEX. About this notice: This notice was issued by Kristian Flaten, CFO, on 20 June 2025 at 04:15 CET on behalf of IDEX Biometrics ASA. The information shall be disclosed according to section 4-2 of the Norwegian Securities Trading Act (STA) and published in accordance with section 5-12 of the STA.

VANCOUVER, British Columbia, June 19, 2025 (GLOBE NEWSWIRE) — Prime Mining Corp. (“Prime” or the “Company”) (TSX: PRYM) (OTCQX: PRMNF) (Frankfurt: O4V3) announces that shareholder voting at the Company’s Annual General and Special Meeting of shareholders held on June 19, 2025 (the “Meeting”) has resulted in the election of all the directors listed as nominees in management’s information circular dated May 5, 2025 (the “Circular”), as well as the approval of all matters presented. Summaries of the results of voting are provided below. Prime is focused on the exploration and development of its wholly owned Los Reyes gold-silver project in Sinaloa State, Mexico (“Los Reyes” or the “Project”). Recent highlights include:Announcement that the Company is targeting the delivery of a Preliminary Economic Assessment (“PEA”)...

MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental theranostic programs and commercial products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting being held in New Orleans, Louisiana (U.S.) from June 21 – 24. Presentation highlights include the ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer, preclinical data on Telix’s TLX252 alpha therapy candidate in CAIX1 -expressing tumors in combination with DDRIs2, and clinical study data on Illuccix® impact on decision-making. Two sponsored symposia will highlight innovation in precision diagnostics, the first on CAIX-PET3 imaging in renal...